famotidine has been researched along with Bone Cancer in 3 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 5.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 1.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, W | 2 |
| Knupp, C | 1 |
| Quan, F | 1 |
| Walker, P | 1 |
| Ramirez, M | 1 |
| Taylor, WC | 1 |
| Vinogradov, M | 1 |
| Khan, N | 1 |
| Jackson, S | 1 |
| Quan, WD | 1 |
| Quan, FM | 1 |
| King, LA | 1 |
| Walker, PR | 1 |
3 other studies available for famotidine and Bone Cancer
| Article | Year |
|---|---|
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2010 |
High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Drug Therapy, Combination; Famotidine; Female; H | 2004 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |